SCHEMBL3123335

SCHEMBL3123335

CCOc1cc(N(Cc2cnco2)c2ccc(C(=O)O)cc2)ccc1OC(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 14/20 0.42
RXRB P28702 2/20 0.42
RXRG P48443 2/20 0.42
HRH4 Q9H3N8 1/20 0.40
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
RAB9A P51151 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PPARG P37231 1/20 0.38
CIT O14578 1/20 0.36
GAK O14976 1/20 0.36
PRKX P51817 1/20 0.36
PRKCQ Q04759 1/20 0.36
AAK1 Q2M2I8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3194660 0.92 PDE4A (0.40) RXRARXRBRXRGPPARGCIT
SCHEMBL3117544 0.92 HRH4 (0.39) RXRARXRBRXRGHRH4LMNA
SCHEMBL3202322 0.91 RXRA (0.43) RXRARXRBRXRGHRH4LMNA
SCHEMBL3129423 0.91 POLB (0.41) RXRARXRBRXRGLMNAMAPK1
SCHEMBL3213414 0.90 RXRA (0.48) RXRARXRBRXRGPPARGCIT
SCHEMBL3131933 0.89 HRH4 (0.41) RXRARXRBRXRGHRH4LMNA
SCHEMBL3126123 0.89 HRH4 (0.38) RXRARXRBRXRGHRH4LMNA
SCHEMBL3192998 0.89 TSHR (0.46) RXRARXRBRXRGHRH4MAPK1
SCHEMBL3215695 0.88 PDE4D (0.41) RXRARXRBRXRG
SCHEMBL3194503 0.88 RXRA (0.53) RXRARXRBRXRGHRH4PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B RXRA 2856/4885RXRB 2676/4885RXRG 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.